卡格列净(一种钠-葡萄糖协同转运蛋白2抑制剂)对1型糖尿病患者经动态血糖监测评估的血糖终点及患者报告结局的影响
这项随机双盲研究纳入351例1型糖尿病患者,接受卡格列净100或300 mg或安慰剂治疗18周。卡格列净改善了血糖变异性指标,并与治疗满意度提高相关;但原文指出卡格列净未被批准用于1型糖尿病治疗,目前不应在1型糖尿病患者中使用。
要点
- 卡格列净100和300 mg较安慰剂降低9点SMBG测得的日平均血糖和SD。
- CGM亚组中卡格列净100和300 mg较安慰剂降低平均血糖和血糖SD。
- 卡格列净增加目标血糖范围内时间并减少高于目标水平时间,治疗满意度改善。
核心结论
- 在1型糖尿病患者中,卡格列净改善了血糖变异性指标,并与治疗满意度改善相关。
- 原文指出尽管研究显示卡格列净在1型糖尿病中有潜在获益,但卡格列净未被批准用于1型糖尿病治疗,目前不应在1型糖尿病患者中使用。
研究设计与样本
- 随机双盲研究,351例1型糖尿病患者接受卡格列净100或300 mg或安慰剂治疗18周。
- 采用9点自我血糖监测(SMBG)图谱评估日平均血糖和SD从基线的变化。
- 89例参与者亚组接受动态血糖监测(CGM),评估平均血糖、血糖变异性指标及血糖范围内时间。
- 采用糖尿病治疗满意度问卷评估治疗满意度变化(n=328)。
主要发现
- 第18周时,卡格列净100和300 mg较安慰剂降低9点SMBG测得的日平均血糖和SD。
- CGM测得的平均血糖变化:卡格列净100 mg为-1.2 mmol/L、300 mg为-0.7 mmol/L、安慰剂为0.6 mmol/L。
- CGM测得的血糖SD变化:卡格列净100 mg为-0.3 mmol/L、300 mg为-0.7 mmol/L、安慰剂为0.1 mmol/L。
- 目标范围内时间(血糖>3.9至≤10.0 mmol/L)变化:卡格列净100 mg为11.6%、300 mg为10.1%、安慰剂为-3.5%。
- 高于目标水平时间(血糖>10.0 mmol/L)变化:卡格列净100 mg为-12.7%、300 mg为-7.6%、安慰剂为5.7%。
关键数值与推荐
- 目标血糖范围定义为血糖>3.9至≤10.0 mmol/L。
- 高于目标水平定义为血糖>10.0 mmol/L。
临床怎么用
- 原文指出卡格列净未被批准用于1型糖尿病治疗,目前不应在1型糖尿病患者中使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic parameters and measures of glucose variability assessed by a 9-point self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) profiles, and patient-reported outcomes as an add-on to insulin among participants with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this randomized, double-blind study, 351 participants received canagliflozin 100 or 300 mg or placebo for 18 weeks. Change from baseline in daily mean glucose and SD was measured using a 9-point SMBG profile. In a subset of 89 participants who underwent CGM, the change from baseline in mean glucose, measures of glycemic variability (SD, coefficient of variation, and mean amplitude of glycemic excursions), and time spent in glycemic ranges were assessed. Change in treatment satisfaction was evaluated using the Diabetes Treatment Satisfaction Questionnaire (n = 328). RESULTS: At week 18, reductions in daily mean glucose and SD measured using the 9-point SMBG profile were seen with canagliflozin 100 and 300 mg versus placebo. Reductions in mean glucose (-1.2, -0.7, and 0.6 mmol/L) and measures of glycemic variability assessed by CGM, such as changes in glucose SD (-0.3, -0.7, and 0.1 mmol/L), were also seen with canagliflozin 100 and 300 mg versus placebo, respectively. Canagliflozin 100 and 300 mg were associated with increases in time spent within target (glucose >3.9 to ≤10.0 mmol/L) compared with placebo (11.6%, 10.1%, and -3.5%, respectively) and commensurate reductions in time spent above the target level (glucose >10.0 mmol/L; -12.7%,-7.6%, and 5.7%, respectively). Participants showed greater improvement in treatment satisfaction with canagliflozin versus placebo; reductions in insulin dose, SD of glucose, and body weight contributed to the relationship between canagliflozin and satisfaction change. CONCLUSIONS: Canagliflozin improved indices of glycemic variability and was associated with improvement in treatment satisfaction versus placebo over 18 weeks among participants with type 1 diabetes. Although these data from this study demonstrate the potential benefits of canagliflozin in people with type 1 diabetes, canagliflozin is not approved for the treatment of type 1 diabetes and should not currently be used in people with type 1 diabetes.
引用
- Rodbard HW, Peters AL, Slee A, et al. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. Diabetes Care. 2016. PMID: 27899497. doi:10.2337/dc16-1353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。